Peptide Decoding

Can You Switch From Semaglutide to Tirzepatide? What the Studies Found

By Allison Thorne · Editorial standards
Published November 17, 2026
Two capped glass vials, one clear and one containing turquoise liquid, on a pale blue surface

In the clearest study of switching from semaglutide to tirzepatide, 61 people made the move. They went on to lose 5.3% of their body weight in six months.1 Why they switched made a big difference. People whose weight had stalled after a real loss did far better than people who had barely lost any.

No trial has tested switching by assigning people to it, so the evidence is thin. What exists is one study that looked back at the records of 61 switchers and a tiny report from Japan. There is also a large count of people moved from one drug to the other by an insurance change, and it has no weight data at all.

How much weight do people lose after switching to tirzepatide?

The 61 semaglutide switchers in a 2026 study published in Obesity lost 5.3% of their total body weight over six months after starting tirzepatide.1 For someone starting at 250 pounds, that is about 13 pounds, a conversion this page made from the study's percentage.

The study, led by Barenbaum and colleagues, reviewed the charts of adults started on tirzepatide between May 2022 and January 2023, before tirzepatide was approved for weight management.12 Of 941 charts, 293 met its criteria. Everyone in the switching group had been on semaglutide at the doses used for weight loss for at least a month before moving over.1 Six months is short, and the design looks backward at records instead of assigning people to a drug. The figure describes what happened to these patients, and it cannot say what a switch would do for anyone else.

The same evidence covers moving from Ozempic or Wegovy, both semaglutide, to Mounjaro or Zepbound, both tirzepatide.

Why do people switch from semaglutide to tirzepatide?

People switch from semaglutide to tirzepatide for three broad reasons in the evidence: their weight stalled, semaglutide did little for them, or their coverage changed. The Barenbaum study recorded switching for non-response, for a plateau or for other reasons, and its results cover the first two.1 Coverage drove the biggest movement on record, and it ran the other way. When CVS Caremark changed its formulary in 2025, switching away from tirzepatide rose more than sixteenfold in a month, mostly to semaglutide.3

Cost and supply sit in the background. GLP-1 users in the CDC's 2025 survey who changed how they took their drug cited cost (38%) and availability (36%) most often. That survey did not ask about switching drugs.2

Does it matter why you switch?

The reason behind a switch made the largest difference in the study. Its authors sorted switchers by how they had done on semaglutide, and the two groups ended up far apart.1

Reason for switching, as the study defined it People Weight lost in 6 months on tirzepatide
Plateau: lost at least 5% on semaglutide, then stopped losing 28 8.1%
Non-response: lost under 5% after at least 3 months on semaglutide 33 2.9%
All switchers 61 5.3%

The difference between the two groups was statistically significant, at P < 0.001.1 On a 250-pound person, 8.1% is about 20 pounds and 2.9% about 7.

People who got almost nothing from semaglutide also got relatively little from tirzepatide in this study, while people who had already responded to semaglutide kept losing after the switch. A small study of 61 people cannot say why, and it leaves room for individuals who do much better or worse than their group.

Do people who already lost weight lose less on tirzepatide?

People who had already lost weight before starting tirzepatide lost less on it in the same study. Patients who came in having lost at least 10% of their body weight, by any route, lost 7.2% in six months on tirzepatide. Patients who had not lost that much lost 10.3%.1 The gap held among patients without type 2 diabetes.1

One possible reason is that people further along have less left to lose at the same pace, though the study did not test that. Its authors conclude only that outcomes varied with weight-reduction status, diabetes status and prior response to semaglutide.1

Why would tirzepatide work when semaglutide did not?

Tirzepatide acts on two receptors where semaglutide acts on one. Semaglutide targets the GLP-1 receptor, and tirzepatide targets that receptor and the GIP receptor as well.4

A 2026 genetics study in Nature Metabolism shows one case where the difference mattered. People carrying rare damaging changes in GLP1R, the gene for the GLP-1 receptor, lost 2.4% of their body weight on semaglutide while matched non-carriers lost 8.8%. On tirzepatide, carriers lost 13.3% and non-carriers 15.2%, a gap the study could not separate from chance.4 Those variants turned up in only 33 of 13,725 people, about 1 in 400.4 They explain very few cases of semaglutide disappointing someone. The study's authors call their explanation for tirzepatide's escape, partial compensation through the GIP receptor, speculative.4

A Japanese report followed 15 people with type 2 diabetes who switched to tirzepatide after losing less than 3% on semaglutide. Over three months, weight changes in its two groups did not reach statistical significance, and the authors call the study small, short and retrospective.5

Does the head-to-head trial show what happens when you switch?

The one head-to-head trial does not answer it, because it never switched anyone. SURMOUNT-5 randomized 751 adults without diabetes to tirzepatide or semaglutide for 72 weeks. It was an open-label trial. Average weight loss was 20.2% on tirzepatide and 13.7% on semaglutide.6

Those figures describe people starting one drug, and they say nothing direct about someone who has already spent months on semaglutide. The trial's sponsor was Lilly, the maker of tirzepatide. Our semaglutide vs tirzepatide comparison covers its design and its other results.

How many people switched when CVS Caremark dropped Zepbound?

Monthly switching away from weight-management tirzepatide rose from about 0.6% to 9.7% when CVS Caremark dropped Zepbound in mid-2025, according to Truveta Research.3 CVS Caremark had announced in May 2025 that it would drop Zepbound from its preferred formulary for weight management from July 1, 2025. Wegovy became the preferred alternative. The change did not touch Mounjaro, the diabetes brand of tirzepatide.3

The Truveta dispensing data covered 854,054 adults with overweight or obesity. Before May 2025, about 0.6% of people on weight-management tirzepatide switched drugs each month. The jump to 9.7% came between June and July 2025, and 81.8% of those who switched went to semaglutide.3 Switching stayed near 1.6% through September and returned to about 0.6% from October 2025 to February 2026.3 An earlier version of the same work, presented at the AMCP Annual Meeting, gave slightly different figures: a rise to 10.2%, with 82.4% going to semaglutide, in a cohort of 700,907 followed through September 2025.7 The extended report covers more people over a longer window and comes from the researchers directly, so it is the stronger of the two.

Truveta's authors say their analysis did not evaluate discontinuation, so it may undercount how many people changed course, and neither version measured weight.3 CVS Caremark reversed itself on May 28, 2026, announcing that Zepbound would return to its commercial formularies "as an additional preferred option October 1, 2026", for plans that choose to cover it.8

Can you switch from tirzepatide back to semaglutide?

No study this guide could find reports what happens to weight when people switch from tirzepatide to semaglutide, though the CVS Caremark change moved many people that way.3 The Truveta report presents none, and its authors note only that the two drugs differ in effectiveness, so a switch may change how someone responds.3

The head-to-head trial's averages favor tirzepatide in people starting fresh.6 No published data show whether someone already doing well on tirzepatide keeps their loss after a forced move to semaglutide. Our guide to what happens when you stop covers what studies measured after people came off these drugs altogether.

Is there a dose conversion between semaglutide and tirzepatide?

No conversion appears in the Zepbound label. It gives no separate instructions for people coming from semaglutide or any other GLP-1 drug.9 Charts that match a semaglutide dose to an equivalent tirzepatide dose circulate online. One published framework describes itself in its title as an expert consensus, meaning agreement among clinicians, not a trial result.10

Peptide Decoding does not publish dose conversions. A switch, and the dose that goes with it, is a prescribing decision.

Can you take semaglutide and tirzepatide together?

The Zepbound label advises against taking tirzepatide together with semaglutide or any other GLP-1 drug. Its limitations of use state that coadministration with other tirzepatide-containing products "or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended", and semaglutide is a GLP-1 receptor agonist.9 Our guide to stacking GLP-1 drugs covers why people ask and what is known.

What does the evidence say a switch depends on?

The evidence points to a few things that shaped results, and it leaves several more open.

  • How someone did on semaglutide. People switching at a plateau lost 8.1% on tirzepatide, and people who had barely responded lost 2.9%.1
  • How much they had already lost. People who had lost at least 10% before starting tirzepatide lost less on it.1
  • Coverage. The biggest jump in switching that Truveta recorded followed a formulary change, not a medical one.3
  • Rarely, genetics. About 1 in 400 people carry GLP1R variants that blunted semaglutide but not tirzepatide.4

Several things are not known. No randomized trial has compared switching with staying on semaglutide, and the Barenbaum study stopped at six months.1 Whether side effects change after a switch is also open, since the Barenbaum abstract gives no side effect data and the Japanese report of 15 people recorded no gastrointestinal events.15 None of these studies examined compounded or gray-market versions of either drug.

Common questions

Can you switch from semaglutide to tirzepatide?

Yes, people do switch from semaglutide to tirzepatide, sold as Mounjaro and Zepbound, and the decision belongs to a prescriber. In a 2026 study of 61 switchers, people lost an average of 5.3% of their body weight over six months on tirzepatide.

Can you switch from Ozempic to Mounjaro?

Yes, people switch from Ozempic to Mounjaro, and the evidence on semaglutide and tirzepatide applies because those are the drugs inside them. In a 2026 study, 61 switchers lost 5.3% of body weight in six months on tirzepatide.

How much weight do people lose after switching to tirzepatide?

The 61 semaglutide switchers in a 2026 Obesity study lost 5.3% of body weight over six months on tirzepatide. Those who switched at a plateau lost 8.1%, and those who had not responded to semaglutide lost 2.9%.

Does tirzepatide work if semaglutide did not?

Not very well in the one 2026 study that measured it. People who lost under 5% after at least 3 months on semaglutide lost 2.9% in six months on tirzepatide, far less than people who switched at a plateau.

Does tirzepatide work after a semaglutide plateau?

People who switched at a plateau lost 8.1% of body weight in six months on tirzepatide in a 2026 study, the best result of any switching group it tracked. The group had 28 people.

What is a semaglutide plateau?

In the 2026 Barenbaum study, a plateau meant losing at least 5% of body weight on semaglutide and then holding steady. Many people describe that as semaglutide no longer working, and other studies may define it differently.

What counts as a non-responder to semaglutide?

The 2026 Barenbaum study defined non-response as losing less than 5% of body weight after at least 3 months on semaglutide at weight-loss doses. Definitions vary between studies.

Do people who already lost weight lose less on tirzepatide?

Yes, in the 2026 Barenbaum study people who had already lost at least 10% before starting tirzepatide lost 7.2% in six months on it, while others lost 10.3%.

Is there a semaglutide to tirzepatide dose conversion?

No conversion appears in the Zepbound label. Conversion charts online rest on clinician consensus, not trials, and Peptide Decoding does not publish dose conversions.

Can you take semaglutide and tirzepatide at the same time?

No, the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended, and semaglutide is one.

Can you switch from tirzepatide back to semaglutide?

People do switch from tirzepatide to semaglutide, often because of insurance changes like the 2025 CVS Caremark formulary shift, but no published study found here reports their weight afterward. In the head-to-head trial of people starting fresh, tirzepatide produced more weight loss on average.

Did CVS Caremark make people switch from Zepbound to Wegovy?

Many switched after CVS Caremark made Wegovy its preferred weight-management drug from July 1, 2025. Truveta data showed monthly switching away from weight-management tirzepatide rising from about 0.6% to 9.7% in June and July 2025.

Does CVS Caremark cover Zepbound again?

CVS Caremark announced on May 28, 2026 that Zepbound would return to its commercial formularies as an additional preferred option from October 1, 2026. Plan sponsors decide whether their members get it.

Is tirzepatide stronger than semaglutide?

In SURMOUNT-5, the only head-to-head trial, people lost 20.2% of body weight on tirzepatide and 13.7% on semaglutide over 72 weeks. The trial enrolled people starting one drug and did not test switching.

Do genes affect whether semaglutide or tirzepatide works?

Rare GLP1R gene variants blunted semaglutide weight loss but not tirzepatide's in a 2026 Nature Metabolism study. Only about 1 in 400 people carried one, so the variants explain few poor responses.

Has any trial tested switching from semaglutide to tirzepatide?

No randomized trial of switching from semaglutide to tirzepatide had been published as of November 2026, as far as this page found. The evidence comes from a retrospective study of 61 switchers and a 15-person report from Japan.

Why do people switch from Ozempic or Wegovy to Mounjaro or Zepbound?

People switch from Ozempic or Wegovy for a stalled loss, a weak response, or insurance. The 2026 Barenbaum study sorted switchers by plateau or non-response, and the 2025 CVS Caremark change moved people in the opposite direction for coverage.

Sources

  1. Barenbaum S, Gonzalez A, Verzani Z, Zhao AS, Shukla AP. Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide. Obesity, published March 28, 2026. doi:10.1002/oby.70179. PMID 41902614.
    Read via a reproduction: the published abstract, read on Weill Cornell Medicine's VIVO research record at https://vivo.weill.cornell.edu/display/pubid41902614. The journal page refused the request, so the full text, tables and any side effect data were not read. The abstract's inclusion criterion names a semaglutide dose; this page describes it only as weight-loss doses. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14
  2. Pierce SL, Balasuriya L, Kompaniyets L, Goodman AB. Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults, United States, 2025. MMWR Morb Mortal Wkly Rep 2026;75(44):645-651. https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm.
    Read at source. Cited for its statement that FDA approved tirzepatide for chronic weight management in 2023, and for the reasons survey respondents gave for changing how they took a GLP-1. The official title separates "Adults" and "United States" with a dash, replaced here with a comma under house style. ↩1 ↩2
  3. Farrar KG, Do D, Masters NB, Cartwright BM. Impact of the CVS GLP-1 formulary change. Truveta Research, April 14, 2026. https://www.truveta.com/blog/research/amcp-2026-impact-cvs-glp-1-formulary-change/.
    Read at source. A research report from a health data company, extending an AMCP poster, with data accessed March 20, 2026. It did not evaluate discontinuation or weight, and it did not include insurance class, so many people in the cohort were likely unaffected by the change. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9
  4. Levy ME, Schiabor Barrett KM, Telis N, et al. Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide. Nature Metabolism, published November 11, 2026. https://doi.org/10.1038/s42255-026-01656-z.
    Read at source: the open-access PDF on nature.com, read in fragments and checked against verbatim text. Eight of the 21 authors are employees of Helix, whose network supplied the data. ↩1 ↩2 ↩3 ↩4 ↩5
  5. Kurinami N, Takada M, Sugiyama S, et al. Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus. Endocrinology and Metabolism 2025;40(6):1012-1015. doi:10.3803/EnM.2025.2420. https://e-enm.org/journal/view.php?number=2646.
    Read at source. A brief report from a single hospital in Japan. Its two groups were defined by how the tirzepatide dose was raised; this page does not report the doses. ↩1 ↩2
  6. Eli Lilly and Company. Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in SURMOUNT-5. Company release, May 11, 2025. https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy.
    Read at source. A company document from the trial's sponsor, used for the trial's design, size and primary result, published in The New England Journal of Medicine (NCT05822830). The figures are the treatment-regimen estimand. ↩1 ↩2
  7. Contreras B. CVS Caremark formulary change linked to brief rise in GLP-1 switching. Managed Healthcare Executive, April 16, 2026. https://www.managedhealthcareexecutive.com/view/cvs-caremark-formulary-change-linked-to-brief-rise-in-glp-1-switching-amcp-annual-2026.
    Read via a reproduction: a trade press report of the AMCP abstract. This page did not read the abstract directly. Cited only for the abstract's figures. They differ from the extended report in source 3. ↩1
  8. CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options. May 28, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.
    Read at source. A company announcement. The release itself does not name the 2025 change by year; the July 1, 2025 effective date comes from source 3. ↩1
  9. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s050lbl.pdf.
    Read at source on accessdata.fda.gov, both halves of the document. Cited for the limitations of use and for the absence of any instruction about switching from another GLP-1 drug. ↩1 ↩2
  10. Switching between semaglutide and tirzepatide in obesity management: an expert-consensus framework for approximate clinical efficacy-matched switching doses. Listing on ResearchGate. https://www.researchgate.net/publication/417138035_Switching_between_semaglutide_and_tirzepatide_in_obesity_Management_an_expert-consensus_framework_for_approximate_clinical_Efficacy-matched_switching_doses.
    Unverified. Only the title was seen, in search results. The journal, authors and content were not read, and this page uses nothing from it beyond what its title says it is. ↩1

Citing this page: Peptide Decoding. Can You Switch From Semaglutide to Tirzepatide? What the Studies Found. Figures from Barenbaum et al., Obesity, March 2026; the Zepbound prescribing information, April 2026; Levy et al., Nature Metabolism, November 2026; Kurinami et al., Endocrinology and Metabolism, 2025; Lilly's SURMOUNT-5 release, May 2025; Truveta Research, April 2026; and CVS Health, May 2026. Reviewed November 14, 2026. https://peptidedecoding.com/guides/switching-semaglutide-to-tirzepatide

Keep reading

The peptide stuff worth knowing.

Get new guides, tools, compound pages, and important peptide news in your inbox 1–3 times a month. If there’s nothing worth sending, we don’t send one.